Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230023/S012

GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis

W. L. Gore & Associates, Inc. · Decision date Jul 1, 2026

FDA DECISIONP230023/S012

What did the FDA approve?

FDA records P230023/S012 as a supplement to PMA P230023, with the supplement type “Special (Immediate Track)”. The recorded decision is approval, dated Jul 1, 2026.

FDA approval order statement

Approval of updates to the IFU (new warning statements)
Regulatory pathway
PMA supplement
Supplement type
Special (Immediate Track)
Clinical specialty
Cardiovascular
Decision date
Jul 1, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P230023/S012
Regulatory pathway
PMA supplement
Product code
QZK
Decision code
APPR
Decision date
Jul 1, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Endovascular system for treatment of thoracoabdominal and pararenal aortic lesions.

Product code
QZK
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P230023/S009 · Related supplement

    GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis

  2. P230023/S010 · Related supplement

    GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis

  3. P230023/S011 · Related supplement

    GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis (TAMBE)

  4. P230023/S012 received

    Application receipt date recorded by FDA.

  5. P230023/S012 · FDA decision

    Special (Immediate Track)

Timeline entries are records held by MedtechLedger for P230023. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230023

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

W. L. Gore & Associates, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3450 W. Kiltie Ln., Flagstaff, AZ, 86005

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records